Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Clinical evidence

Cutaneous adverse-event case series

7 evidence topics · 1 source

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using cutaneous adverse events as the safety outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Age
MeasureQuoted value
Mean age, years“71.1”
Age range, years“52–88”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This single-center case series included seven participants, with skin disorders reported in five and treatment discontinuation because of severe cutaneous adverse events in one. The sample size and lack of a comparator limit estimation of population-level risk and comparative tolerability.